SUNFISH
E561097
SUNFISH is a pivotal clinical trial program evaluating the efficacy and safety of risdiplam in patients with spinal muscular atrophy (SMA).
All labels observed (1)
| Label | Occurrences |
|---|---|
| SUNFISH canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6004784 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: SUNFISH Context triple: [risdiplam, clinicalTrialProgram, SUNFISH]
-
A.
Fisk
Fisk is a surname most famously associated with Carlton Fisk, a Hall of Fame Major League Baseball catcher known for his long career with the Boston Red Sox and Chicago White Sox.
-
B.
Karpf
Karpf is a surname of German origin, likely a variant of "Karp," borne by various individuals across German-speaking regions.
-
C.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
D.
Pomfret
Pomfret is a small, historic town in northeastern Connecticut known for its rural character, scenic landscapes, and prestigious boarding schools.
-
E.
Marlin
Marlin is the cautious and devoted clownfish father from Pixar's "Finding Nemo" franchise, known for his ocean-spanning quest to rescue his son.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: SUNFISH Target entity description: SUNFISH is a pivotal clinical trial program evaluating the efficacy and safety of risdiplam in patients with spinal muscular atrophy (SMA).
-
A.
Fisk
Fisk is a surname most famously associated with Carlton Fisk, a Hall of Fame Major League Baseball catcher known for his long career with the Boston Red Sox and Chicago White Sox.
-
B.
Karpf
Karpf is a surname of German origin, likely a variant of "Karp," borne by various individuals across German-speaking regions.
-
C.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
D.
Pomfret
Pomfret is a small, historic town in northeastern Connecticut known for its rural character, scenic landscapes, and prestigious boarding schools.
-
E.
Marlin
Marlin is the cautious and devoted clownfish father from Pixar's "Finding Nemo" franchise, known for his ocean-spanning quest to rescue his son.
- F. None of above. chosen
Statements (36)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial program
ⓘ
interventional clinical study ⓘ |
| abbreviation | SUNFISH ⓘ |
| developedBy |
PTC Therapeutics
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| drugClassStudied | SMN2 splicing modifier ⓘ |
| endpointType |
motor function outcomes
ⓘ
safety outcomes ⓘ |
| evaluates | risdiplam NERFINISHED ⓘ |
| geographicScope | multinational ⓘ |
| hasPart |
SUNFISH Part 1
NERFINISHED
ⓘ
SUNFISH Part 2 NERFINISHED ⓘ |
| hasPhase |
Phase 2
ⓘ
Phase 3 ⓘ |
| indicationStudied | treatment of spinal muscular atrophy ⓘ |
| interventionType | oral small-molecule therapy ⓘ |
| investigationalDrug | risdiplam ⓘ |
| mechanismOfActionStudied | SMN2 pre-mRNA splicing modification ⓘ |
| primaryObjective | evaluate efficacy of risdiplam in SMA ⓘ |
| relatedTo |
FIREFISH clinical trial
ⓘ
JEWELFISH clinical trial ⓘ RAINBOWFISH clinical trial ⓘ |
| routeOfAdministration | oral ⓘ |
| secondaryObjective | evaluate safety of risdiplam in SMA ⓘ |
| sponsor |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| sponsorCountry | Switzerland NERFINISHED ⓘ |
| studiesCondition | spinal muscular atrophy ⓘ |
| studyDesign |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| targetsPopulation |
adult SMA patients
ⓘ
patients with spinal muscular atrophy ⓘ pediatric SMA patients ⓘ |
| therapeuticArea |
neuromuscular disease
ⓘ
rare disease ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: SUNFISH Description of subject: SUNFISH is a pivotal clinical trial program evaluating the efficacy and safety of risdiplam in patients with spinal muscular atrophy (SMA).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.